India, July 2 -- Seer, Inc. (SEER), a biotechnology company specializing in proteomics, announced it has received an unsolicited, non-binding acquisition proposal from its Chair and Chief Executive Officer, Omid Farokhzad, M.D. The offer seeks to acquire all outstanding shares of Seer's Class A common stock for $2.45 per share in cash, along with two contingent value rights (CVRs) tied to future milestones.
The company confirmed that the full text of the proposal will be filed with the Securities and Exchange Commission on Form 8-K. Seer's Board of Directors has formed a Special Committee composed entirely of independent directors to evaluate the proposal and consider other strategic alternatives. The committee will be supported by indepen...